Want to see SOPH full AI Analyst Report?
SOPH Stock Chart & Stats
$5.28
-$0.07(-2.14%)
At close: 4:00 PM EST
$5.28
-$0.07(-2.14%)
Day’s Range― - ―
52-Week Range$2.92 - $6.77
Previous CloseN/A
Volume4.05K
Average Volume (3M)100.95K
Market Cap
$545.32M
Enterprise Value$349.16
Total Cash (Recent Filing)$65.39M
Total Debt (Recent Filing)$62.42M
Price to Earnings (P/E)―
Beta1.28
Next Earnings
Aug 04, 2026EPS Estimate
-0.21Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.18
Shares Outstanding83,895,260
10 Day Avg. Volume137,858
30 Day Avg. Volume100,949
Financial Highlights & Ratios
PEG Ratio-0.17
Price to Book (P/B)6.69
Price to Sales (P/S)4.08
P/FCF Ratio-8.17
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$9.00Price Target Upside70.45% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-0.81
Revenue Forecast (FY)$93.40M
Bulls Say, Bears Say
Bulls Say
Recurring, Usage‑based Revenue ModelA mixed subscription and per‑analysis pricing model ties revenue to durable lab testing activity while preserving recurring contract value. High net dollar retention (117%) and <1% annualized churn indicate strong customer stickiness and predictable revenue expansion as platform volumes scale.
High Adjusted Gross MarginsSustained ~75% adjusted gross margin demonstrates strong unit economics from a cloud analytics platform with low incremental cost per analysis. Healthy gross profit ($16.4M in Q1, +22% YoY) supports operating leverage as volumes grow and underpins management's plan to move toward adjusted‑EBITDA breakeven by end‑2026.
Strategic Partnerships And Biopharma TractionPartnerships with MSK and commercial ties to AstraZeneca, J&J and others deepen clinical data access and create co‑development channels for companion diagnostics and RWE. Biopharma revenue turned modestly positive in Q1 and can drive higher‑value, less price‑sensitive volume over the medium term.
Bears Say
High Cash Burn And Operating LossesMaterial negative operating and free cash flow create ongoing funding needs until scale and operating discipline deliver sustained profitability. Quarterly cash burn (Q1 $19.5M) and continued investment in sales, lab and legal support the growth plan but raise dilution and refinancing risk if margins or revenue ramps slip.
Rising Leverage And Weakened Balance SheetLeverage has increased materially and equity returns remain deeply negative, reducing financial flexibility. Moderate absolute debt combined with ongoing losses elevates interest and covenant risks and can constrain strategic choices, especially if cash generation does not improve as forecast.
Legal, FX And Execution RisksPersistent litigation expenses, significant currency translation pressure on Swiss cost base, and a back‑half weighted revenue profile create execution risk. Slower customer onboarding or adverse FX/litigation outcomes could delay the path to adjusted EBITDA breakeven and increase near‑term cash needs.
SOPHiA GENETICS News
SOPH FAQ
What was SOPHiA GENETICS’s price range in the past 12 months?
SOPHiA GENETICS lowest stock price was $2.92 and its highest was $6.77 in the past 12 months.
What is SOPHiA GENETICS’s market cap?
SOPHiA GENETICS’s market cap is $545.32M.
When is SOPHiA GENETICS’s upcoming earnings report date?
SOPHiA GENETICS’s upcoming earnings report date is Aug 04, 2026 which is in 12 days.
How were SOPHiA GENETICS’s earnings last quarter?
SOPHiA GENETICS released its earnings results on May 05, 2026. The company reported -$0.27 earnings per share for the quarter, missing the consensus estimate of -$0.232 by -$0.038.
Is SOPHiA GENETICS overvalued?
According to Wall Street analysts SOPHiA GENETICS’s price is currently Undervalued.
Does SOPHiA GENETICS pay dividends?
SOPHiA GENETICS does not currently pay dividends.
What is SOPHiA GENETICS’s EPS estimate?
SOPHiA GENETICS’s EPS estimate is -0.21.
How many shares outstanding does SOPHiA GENETICS have?
SOPHiA GENETICS has 83,895,260 shares outstanding.
What happened to SOPHiA GENETICS’s price movement after its last earnings report?
SOPHiA GENETICS reported an EPS of -$0.27 in its last earnings report, missing expectations of -$0.232. Following the earnings report the stock price went down -4.159%.
Which hedge fund is a major shareholder of SOPHiA GENETICS?
Currently, no hedge funds are holding shares in SOPH
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
SOPHiA GENETICS Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$9.00 (70.45% Upside)
$9.00 (70.45% Upside)
Blogger Sentiment
Bearish
SOPH Sentiment 100%
Sector Average 66%
Sector Average 66%
Hedge Fund Trend
Increased
By 1.4M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $97.8K over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
21.40%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
7.00%
Trailing 12-Months
Company Description
SOPHiA GENETICS
SOPHiA GENETICS S.A. operates as a specialized company within the healthcare technology sector. The firm provides the SOPHiA DDM platform, a cloud-native Software-as-a-Service (SaaS) solution engineered to analyze diverse multimodal datasets and various diagnostic inputs, thereby extracting valuable insights. This platform, together with its related offerings and services, is widely adopted by hospitals, laboratories, and biopharmaceutical organizations across the globe. Founded in 2011, SOPHiA GENETICS S.A. is headquartered in Saint-Sulpice, Switzerland.
SOPH Stock 12 Month Forecast
Average Price Target
$9.00
▲(70.45% Upside)
Technical Analysis
Schrodinger
―
Zhongchao
―
GeneDx Holdings
―
Definitive Healthcare Corp
―
Omada Health, Inc.
―
Ownership Overview
9.09% Insiders
2.07% Mutual Funds
0.45% Other Institutional Investors
88.28% Public Companies and
Individual Investors